SCHEMBL20229514

SCHEMBL20229514

CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@H](COCc2ccccc2)OC(C)[C@H]1OC(C)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.53
▸ LMNA P02545 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KMT2A Q03164 1/20 0.45
▸ NT5E P21589 1/20 0.43
▸ CA12 O43570 4/20 0.43
▸ CA1 P00915 4/20 0.43
▸ CA2 P00918 4/20 0.43
▸ CA4 P22748 4/20 0.43
▸ CA6 P23280 4/20 0.43
▸ CA5A P35218 4/20 0.43
▸ CA7 P43166 4/20 0.43
▸ CA9 Q16790 4/20 0.43
▸ CA13 Q8N1Q1 4/20 0.43
▸ CA14 Q9ULX7 4/20 0.43
▸ CA5B Q9Y2D0 4/20 0.43
▸ TACR2 P21452 3/20 0.41
▸ PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20306742 0.91 NT5E (0.51) TSHRNT5ETACR2PTPN1
SCHEMBL16317729 0.87 TSHR (0.53) TSHRLMNAALDH1A1CYP2D6MAPK1
SCHEMBL2449854 0.87 TSHR (0.53) TSHRLMNAALDH1A1CYP2D6MAPK1
SCHEMBL19588716 0.87 LMNA (0.55) TSHRLMNAALDH1A1CYP2D6MAPK1
SCHEMBL1130099 0.87 LMNA (0.55) TSHRLMNAALDH1A1CYP2D6MAPK1
SCHEMBL2449852 0.87 TSHR (0.53) TSHRLMNAALDH1A1CYP2D6MAPK1
SCHEMBL26824441 0.87 LMNA (0.55) TSHRLMNAALDH1A1CYP2D6MAPK1
SCHEMBL15514388 0.87 LMNA (0.55) TSHRLMNAALDH1A1CYP2D6MAPK1
SCHEMBL22677739 0.87 TACR2 (0.46) TSHRNT5ETACR2PTPN1SELP
SCHEMBL26120777 0.86 TSHR (0.52) TSHRLMNAALDH1A1CYP2D6MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319526-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEAGEN INC. (US) 2022-05-03 — — US disclosed
US-10443035-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2019-10-15 — — US disclosed
US-20190276796-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC. 2019-09-12 — — US disclosed
US-20180155677-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC. 2018-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155677-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION FUT5, FUCA2, FCGR3B TSHR 1665/4885LMNA 2329/4885ALDH1A1 3059/4885
US-10443035-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation FUT5, FUCA2, FCGR3B TSHR 1665/4885LMNA 2329/4885ALDH1A1 3059/4885
US-20190276796-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION FUT5, FUCA2, FCGR3B TSHR 1665/4885LMNA 2329/4885ALDH1A1 3059/4885
US-11319526-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation FUT5, FUCA2, FCGR3B TSHR 1665/4885LMNA 2329/4885ALDH1A1 3059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback